AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$BBIO

Kumar Neil sold $691K of BBIO (indirect holdings)

Kumar Neil (Chief Executive Officer) sold 10,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $69.08 ($69.01–$69.57, $0.69M total) across 2 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Sep 21, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, likely limiting market reaction.

02

Market read

Provides a fresh data point for traders tracking insider activity, but limited actionable impact.

03

What to watch

CEO's 10b5-1 plan may be unrelated to company fundamentals.

Relevance 4/10Novelty 4/10Timing: post filing 2026-09-21

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

CEO Kumar Neil sold $691K of BBIO shares via a 10b5-1 plan on 2026-09-17.

Expected impact

Potential short-term dip of 1-2% if market reacts.

Evidence & confidence

Insider sales often cause slight negative sentiment; however, the transaction is pre‑arranged and modest in scale.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No regional effect beyond BBIO's trading venue.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    BridgeBio Pharma, Inc.

    Biotech firm listed on NASDAQ under BBIO.

  • Executive
    Kumar Neil

    CEO and Director of BridgeBio Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

OCT 7
$BBIOMedAI 9/10

BridgeBio Pharma stock rating reiterated at Buy by Canaccord

Canaccord reiterated a Buy rating and $106 price target for BridgeBio Pharma (BBIO) after positive cardiac data from its LGMD2I/R9 treatment program. The company's stock trades at $66.96, below the target. Analysts maintain a Strong Buy consensus with targets ranging from $80 to $156. BridgeBio estimates a 90% success probability and peak sales of $1.3B by 2034 for the treatment.

investing.com2 min
OCT 6
$BBIOHigh

FDA Accepts BridgeBio's Infigratinib NDA For Priority Review

BridgeBio Pharma (BBIO) announced the FDA accepted its NDA for infigratinib to treat achondroplasia in children, granting Priority Review. The PDUFA target date is February 4, 2027. The NDA is backed by positive Phase 3 study results showing significant improvements in height velocity and body proportionality. BBIO shares rose 1.65% on Friday and are up 3.42% in premarket trading.

rttnews.com2 min
OCT 6
$BBIOHigh

H.C. Wainwright reiterates Buy on BridgeBio stock, cites cardiac data

H.C. Wainwright reiterated a Buy rating and $120 price target on BridgeBio Pharma (BBIO) after positive cardiac data from its muscular dystrophy treatment. The stock is currently at $66.14, with analysts maintaining a Strong Buy consensus and targets ranging from $80 to $157. BridgeBio reported 202% revenue growth and 94% gross margins over the last year, according to InvestingPro.

investing.com1 min
OCT 6
$BBIOMed

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio Pharma (BBIO) announced FDA acceptance of its NDA for oral infigratinib to treat children with achondroplasia, with a Priority Review and PDUFA target date of February 4, 2027. The PROPEL 3 trial met primary and key secondary endpoints, showing significant improvements in height velocity and body proportionality. If approved, it would be the first oral therapy for this condition.

globenewswire.com3 min